CTLA4 and cancer: Cancer immunotherapy, particularly immune-checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 (PD-1) inhibitory immune checkpoints, has transformed the management of advanced cancers.